Ovarian Response Data
CDK4/6
Overall (N = 515)
AML (N = 23)
Head and Neck (N = 24)
Myeloma (N = 20)
Kidney (N = 27)
Breast (N = 46)
Bladder (N = 27)
Melanoma (N = 40)
Upper GI (N = 25)
Lymphoma (N = 30)
Liver (N = 20)
Sarcoma (N = 54)
Pancreas (N = 27)
Lung (N = 57)
Colon (N = 29)
Ovarian (N = 35)
Endometrial (N = 20)
SCLC (N = 11)
Overall (N = 515)
AML (N = 24)
Melanoma (N = 40)
Head and Neck (N = 24)
Liver (N = 19)
Sarcoma (N = 54)
Lymphoma (N = 30)
Myeloma (N = 20)
Lung (N = 57)
Pancreas (N = 27)
Kidney (N = 27)
Bladder (N = 27)
Upper GI (N = 25)
Ovarian (N = 35)
Colon (N = 29)
Endometrial (N = 20)
SCLC (N = 11)
Overall (N = 514)  
AML (N = 23)  
Melanoma (N = 40)  
Lymphoma (N = 30)  
Head and Neck (N = 24)  
Sarcoma (N = 53)  
Pancreas (N = 27)  
Kidney (N = 27)  
Breast (N = 46)  
Liver (N = 19)  
Galon (N = 29)  
Bladder (N = 27)  
Upper GI (N = 15)  
Lung (N = 57)  
Myeloma (N = 20)  
Ovarian (N = 36)  
Endometrial (N = 20)  
SCLC (N = 11)
olaparib: IC50 Distribution By Cancer Type

IC50 (um)

Primary Site

Overall (N = 521)
Sarcoma (N = 55)
Melanoma (N = 20)
Lymphoma (N = 30)
Upper GI (N = 25)
AAAs (N = 23)
Breast (N = 46)
Melanoma (N = 40)
Endometrial (N = 20)
Ovarian (N = 38)
Lung (N = 68)
Liver (N = 20)
Bladder (N = 27)
Colon (N = 29)
Head and Neck (N = 26)
Kidney (N = 26)
Pancreas (N = 28)
talazoparib: IC50 Distribution By Cancer Type

Cutoff: IC50 = 0.025
PI3K-alpha
Overall (N = 513)
Liver (N = 19)
Myeloma (N = 20)
AML (N = 24)
Head and Neck (N = 24)
Breast (N = 44)
Upper GI (N = 25)
SCLC (N = 11)
Ovarian (N = 36)
Bladder (N = 27)
Pancreas (N = 27)
Endometrial (N = 29)
Lymphoma (N = 30)
Lung (N = 57)
Colon (N = 29)
Kidney (N = 27)
Sarcoma (N = 54)
Melanoma (N = 40)
Overall (N = 511)
Liver (N = 19)
Bladder (N = 27)
SCLC (N = 11)
Myeloma (N = 20)
Lymphoma (N = 30)
Head and Neck (N = 24)
Ovarian (N = 35)
Breast (N = 44)
AML (N = 24)
Upper GI (N = 25)
Kidney (N = 27)
Pancreas (N = 27)
Endometrial (N = 19)
Sarcoma (N = 53)
Lung (N = 57)
Colon (N = 29)
Melanoma (N = 40)
PF-4989216: IC50 Distribution By Cancer Type

Overall (N = 513)

Liver (N = 19)
SCLC (N = 11)
Breast (N = 44)
Head and Neck (N = 24)
Upper GI (N = 25)
Bladder (N = 27)
Myeloma (N = 20)
Lymphoma (N = 30)
Endometrial (N = 19)
Pancreas (N = 27)
Ovarian (N = 36)
Lung (N = 57)
AML (N = 24)
Sarcoma (N = 54)
Kidney (N = 27)
Melanoma (N = 40)
Colon (N = 29)
AKT
BAY-1125976: IC50 Distribution By Cancer Type

Primary Site

- Overall (N = 525)
- Myeloma (N = 20)
- Breast (N = 46)
- AML (N = 25)
- Lymphoma (N = 30)
- SCLC (N = 11)
- Prostate (N = 5)
- Bladder (N = 27)
- Colon (N = 29)
- Endometrial (N = 20)
- Head and Neck (N = 24)
- Kidney (N = 27)
- Lung (N = 57)
- Liver (N = 19)
- Melanoma (N = 40)
- Ovarian (N = 39)
- Pancreas (N = 27)
- Upper GI (N = 25)
ARQ-092: IC50 Distribution By Cancer Type

Primary Site

Overall (N = 525)
Breast (N = 46)
Lymphoma (N = 30)
Myeloma (N = 20)
Prostate (N = 5)
Liver (N = 19)
Upper GI (N = 25)
Melanoma (N = 40)
Sarcoma (N = 54)
Bladder (N = 27)
Kidney (N = 27)
Head and Neck (N = 24)
AML (N = 25)
Ovarian (N = 39)
Colon (N = 29)
Lung (N = 57)
Endometrial (N = 20)
Pancreas (N = 27)
SCLC (N = 11)
MK-2206: IC50 Distribution By Cancer Type

Overall (N = 517)
Breast (N = 46)
Lymphoma (N = 30)
Myeloma (N = 20)
SCLC (N = 11)
AML (N = 25)
Prostate (N = 5)
Melanoma (N = 40)
Sarcoma (N = 54)
Bladder (N = 27)
Upper GI (N = 25)
Kidney (N = 27)
Endometrial (N = 20)
Head and Neck (N = 24)
Ovarian (N = 39)
Colon (N = 25)
Lung (N = 57)
Liver (N = 11)
Pancreas (N = 27)
MEK162: IC50 Distribution By Cancer Type

Primary Site

- Overall (N = 402)
- Melanoma (N = 50)
- Head and Neck (N = 24)
- Upper GI (N = 8)
- Colon (N = 28)
- Pancreas (N = 27)
- Lung (N = 51)
- Ovarian (N = 34)
- Liver (N = 20)
- Kidney (N = 9)
- Endometrial (N = 20)
- Breast (N = 45)
- Sarcoma (N = 56)
- Lymphoma (N = 27)
- SCLC (N = 3)

IC50 (uM)
Trametinib: IC50 Distribution By Cancer Type

Overall (N = 504)
- Melanoma (N = 46)
- Pancreas (N = 27)
- Colon (N = 29)
- Bladder (N = 28)
- Head and Neck (N = 24)
- Kidney (N = 27)
- Ovarian (N = 39)
- Upper GI (N = 23)
- Liver (N = 20)
- Lung (N = 57)
- Breast (N = 42)
- Endometrial (N = 20)
- Sarcoma (N = 56)
- Lymphoma (N = 37)
- Myeloma (N = 20)
- SCLC (N = 9)